Evaluation of therapeutic effects of FAK inhibition in murine models of atherosclerosis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Takeshi Yamaura, Tatsuhiko Kasaoka, Naoko Iijima, Masaaki Kimura, Shinji Hatakeyama

ABSTRACT

OBJECTIVE: Therapeutic effects of focal adhesion kinase (FAK) inhibition using a small molecule inhibitor was evaluated in apolipoprotein E (apoE) knockout (KO) and low-density lipoprotein receptor (LDLr) KO mouse atherosclerosis models. RESULTS: The prevention trial consisted of an 8-week treatment with an FAK inhibitor concurrent treatment with a high fat (HF)/high cholesterol (HC) diet. The intervention trial consisted of 6- and 8-week treatment after 6- and 8-week pre-loading, respectively, of a HF/HC diet in apoE KO and LDLr KO mice, respectively. The inhibitor was admixed with a HF/HC diet and mice were given free access to the admixture. The FAK inhibitor exhibited marked inhibition against the development of the atherosclerosis in both of prevention and intervention trials at a dose of 0.03% without showing any remarkable toxic properties in biochemical examinations. These results indicated that FAK inhibition might be a possible candidate for novel therapeutic targets against atherosclerosis. More... »

PAGES

200

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13104-019-4220-5

DOI

http://dx.doi.org/10.1186/s13104-019-4220-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113179521

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30940182


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Novartis Institutes for BioMedical Research, Novartis Pharma K.K, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamaura", 
        "givenName": "Takeshi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Institutes for BioMedical Research, Novartis Pharma K.K, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kasaoka", 
        "givenName": "Tatsuhiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Institutes for BioMedical Research, Novartis Pharma K.K, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iijima", 
        "givenName": "Naoko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Institutes for BioMedical Research, Novartis Pharma K.K, Tsukuba, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kimura", 
        "givenName": "Masaaki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hatakeyama", 
        "givenName": "Shinji", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.5551/jat.12.73", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004448205"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1359-6349(08)72065-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006137010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1023725029589", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013068731", 
          "https://doi.org/10.1023/a:1023725029589"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1242/jcs.182097", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020433455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0079-6107(98)00052-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026771490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m303771200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031188359"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2741/1115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070913423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4049/jimmunol.170.12.5912", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075298272"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4196/kjpp.2018.22.2.127", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101334325"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "OBJECTIVE: Therapeutic effects of focal adhesion kinase (FAK) inhibition using a small molecule inhibitor was evaluated in apolipoprotein E (apoE) knockout (KO) and low-density lipoprotein receptor (LDLr) KO mouse atherosclerosis models.\nRESULTS: The prevention trial consisted of an 8-week treatment with an FAK inhibitor concurrent treatment with a high fat (HF)/high cholesterol (HC) diet. The intervention trial consisted of 6- and 8-week treatment after 6- and 8-week pre-loading, respectively, of a HF/HC diet in apoE KO and LDLr KO mice, respectively. The inhibitor was admixed with a HF/HC diet and mice were given free access to the admixture. The FAK inhibitor exhibited marked inhibition against the development of the atherosclerosis in both of prevention and intervention trials at a dose of 0.03% without showing any remarkable toxic properties in biochemical examinations. These results indicated that FAK inhibition might be a possible candidate for novel therapeutic targets against atherosclerosis.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13104-019-4220-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1039457", 
        "issn": [
          "1756-0500"
        ], 
        "name": "BMC Research Notes", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "name": "Evaluation of therapeutic effects of FAK inhibition in murine models of atherosclerosis", 
    "pagination": "200", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13104-019-4220-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113179521"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c4dfcc0fc00ae5bb898f85882b1636f6b93cdb9295ba130badb3dc00e9bc34de"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101462768"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30940182"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13104-019-4220-5", 
      "https://app.dimensions.ai/details/publication/pub.1113179521"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106804_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13104-019-4220-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13104-019-4220-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13104-019-4220-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13104-019-4220-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13104-019-4220-5'


 

This table displays all metadata directly associated to this object as RDF triples.

127 TRIPLES      21 PREDICATES      38 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13104-019-4220-5 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 schema:author N23e65ab8be114aefa390bf84fdc03f83
4 schema:citation sg:pub.10.1023/a:1023725029589
5 https://doi.org/10.1016/s0079-6107(98)00052-2
6 https://doi.org/10.1016/s1359-6349(08)72065-2
7 https://doi.org/10.1074/jbc.m303771200
8 https://doi.org/10.1242/jcs.182097
9 https://doi.org/10.2741/1115
10 https://doi.org/10.4049/jimmunol.170.12.5912
11 https://doi.org/10.4196/kjpp.2018.22.2.127
12 https://doi.org/10.5551/jat.12.73
13 schema:datePublished 2019-12
14 schema:datePublishedReg 2019-12-01
15 schema:description OBJECTIVE: Therapeutic effects of focal adhesion kinase (FAK) inhibition using a small molecule inhibitor was evaluated in apolipoprotein E (apoE) knockout (KO) and low-density lipoprotein receptor (LDLr) KO mouse atherosclerosis models. RESULTS: The prevention trial consisted of an 8-week treatment with an FAK inhibitor concurrent treatment with a high fat (HF)/high cholesterol (HC) diet. The intervention trial consisted of 6- and 8-week treatment after 6- and 8-week pre-loading, respectively, of a HF/HC diet in apoE KO and LDLr KO mice, respectively. The inhibitor was admixed with a HF/HC diet and mice were given free access to the admixture. The FAK inhibitor exhibited marked inhibition against the development of the atherosclerosis in both of prevention and intervention trials at a dose of 0.03% without showing any remarkable toxic properties in biochemical examinations. These results indicated that FAK inhibition might be a possible candidate for novel therapeutic targets against atherosclerosis.
16 schema:genre research_article
17 schema:inLanguage en
18 schema:isAccessibleForFree true
19 schema:isPartOf N1d59b112d5494eceb3453718f2ec62f4
20 Nfd6c74ced4fd4a3ab4643572998ee741
21 sg:journal.1039457
22 schema:name Evaluation of therapeutic effects of FAK inhibition in murine models of atherosclerosis
23 schema:pagination 200
24 schema:productId N4dbd9695d2d045b8b2ab6784f36b5b8f
25 N5baa0a7c925343d4b214cbfdc70489c6
26 N8d3cf680f88a4d9cbac469a1b3eb165c
27 Ncc58bc212f2d41598e78a88f8a6d1063
28 Ncd825a6e374e4e6597a3fb571e6eeaba
29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113179521
30 https://doi.org/10.1186/s13104-019-4220-5
31 schema:sdDatePublished 2019-04-16T06:21
32 schema:sdLicense https://scigraph.springernature.com/explorer/license/
33 schema:sdPublisher N1fdabe35f5f44b1c931486481dd34bc3
34 schema:url https://link.springer.com/10.1186%2Fs13104-019-4220-5
35 sgo:license sg:explorer/license/
36 sgo:sdDataset articles
37 rdf:type schema:ScholarlyArticle
38 N0cc29524e8c64048bb4eb84206a0f6a2 schema:name Novartis Institutes for BioMedical Research, Novartis Pharma K.K, Tsukuba, Ibaraki, Japan
39 rdf:type schema:Organization
40 N179f3363bb8b41f483fd16d7c8f1fbe6 schema:affiliation Ned5de8bca206431cacabcf31db439f21
41 schema:familyName Kasaoka
42 schema:givenName Tatsuhiko
43 rdf:type schema:Person
44 N1d59b112d5494eceb3453718f2ec62f4 schema:issueNumber 1
45 rdf:type schema:PublicationIssue
46 N1fdabe35f5f44b1c931486481dd34bc3 schema:name Springer Nature - SN SciGraph project
47 rdf:type schema:Organization
48 N21f1e94d31c14379a0a9f4e099d24234 schema:name Novartis Institutes for BioMedical Research, Novartis Pharma K.K, Tsukuba, Ibaraki, Japan
49 rdf:type schema:Organization
50 N23e65ab8be114aefa390bf84fdc03f83 rdf:first N2a05954c9cc041c28623f8948ce6f095
51 rdf:rest N5fd495d775e74f6fb9891995a63f3ef5
52 N2a05954c9cc041c28623f8948ce6f095 schema:affiliation Nad1e37984fa2401ea2d82f1d06777663
53 schema:familyName Yamaura
54 schema:givenName Takeshi
55 rdf:type schema:Person
56 N3b4b428d79d441258afa9f235927bf20 schema:affiliation N0cc29524e8c64048bb4eb84206a0f6a2
57 schema:familyName Iijima
58 schema:givenName Naoko
59 rdf:type schema:Person
60 N4dbd9695d2d045b8b2ab6784f36b5b8f schema:name nlm_unique_id
61 schema:value 101462768
62 rdf:type schema:PropertyValue
63 N538913f857334dc9b7c666c06d4be48c rdf:first N6e479f9a21ea45308905632e4dc2bdcb
64 rdf:rest Ne5cebefd1ad449a6a2d6f8d604491c0b
65 N5baa0a7c925343d4b214cbfdc70489c6 schema:name doi
66 schema:value 10.1186/s13104-019-4220-5
67 rdf:type schema:PropertyValue
68 N5fd495d775e74f6fb9891995a63f3ef5 rdf:first N179f3363bb8b41f483fd16d7c8f1fbe6
69 rdf:rest N7d61a8a2a03949eb9c145d39c1e9d4c5
70 N6e479f9a21ea45308905632e4dc2bdcb schema:affiliation N21f1e94d31c14379a0a9f4e099d24234
71 schema:familyName Kimura
72 schema:givenName Masaaki
73 rdf:type schema:Person
74 N7d61a8a2a03949eb9c145d39c1e9d4c5 rdf:first N3b4b428d79d441258afa9f235927bf20
75 rdf:rest N538913f857334dc9b7c666c06d4be48c
76 N8d3cf680f88a4d9cbac469a1b3eb165c schema:name pubmed_id
77 schema:value 30940182
78 rdf:type schema:PropertyValue
79 N9ccceaeb266948e4acbc9682a1bbb5ad schema:affiliation https://www.grid.ac/institutes/grid.419481.1
80 schema:familyName Hatakeyama
81 schema:givenName Shinji
82 rdf:type schema:Person
83 Nad1e37984fa2401ea2d82f1d06777663 schema:name Novartis Institutes for BioMedical Research, Novartis Pharma K.K, Tsukuba, Ibaraki, Japan
84 rdf:type schema:Organization
85 Ncc58bc212f2d41598e78a88f8a6d1063 schema:name dimensions_id
86 schema:value pub.1113179521
87 rdf:type schema:PropertyValue
88 Ncd825a6e374e4e6597a3fb571e6eeaba schema:name readcube_id
89 schema:value c4dfcc0fc00ae5bb898f85882b1636f6b93cdb9295ba130badb3dc00e9bc34de
90 rdf:type schema:PropertyValue
91 Ne5cebefd1ad449a6a2d6f8d604491c0b rdf:first N9ccceaeb266948e4acbc9682a1bbb5ad
92 rdf:rest rdf:nil
93 Ned5de8bca206431cacabcf31db439f21 schema:name Novartis Institutes for BioMedical Research, Novartis Pharma K.K, Tsukuba, Ibaraki, Japan
94 rdf:type schema:Organization
95 Nfd6c74ced4fd4a3ab4643572998ee741 schema:volumeNumber 12
96 rdf:type schema:PublicationVolume
97 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
98 schema:name Medical and Health Sciences
99 rdf:type schema:DefinedTerm
100 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
101 schema:name Cardiorespiratory Medicine and Haematology
102 rdf:type schema:DefinedTerm
103 sg:journal.1039457 schema:issn 1756-0500
104 schema:name BMC Research Notes
105 rdf:type schema:Periodical
106 sg:pub.10.1023/a:1023725029589 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013068731
107 https://doi.org/10.1023/a:1023725029589
108 rdf:type schema:CreativeWork
109 https://doi.org/10.1016/s0079-6107(98)00052-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026771490
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1016/s1359-6349(08)72065-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006137010
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1074/jbc.m303771200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031188359
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1242/jcs.182097 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020433455
116 rdf:type schema:CreativeWork
117 https://doi.org/10.2741/1115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070913423
118 rdf:type schema:CreativeWork
119 https://doi.org/10.4049/jimmunol.170.12.5912 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075298272
120 rdf:type schema:CreativeWork
121 https://doi.org/10.4196/kjpp.2018.22.2.127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101334325
122 rdf:type schema:CreativeWork
123 https://doi.org/10.5551/jat.12.73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004448205
124 rdf:type schema:CreativeWork
125 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
126 schema:name Novartis Pharma AG, Basel, Switzerland
127 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...